Inskip P D, Kleinerman R A, Stovall M, Cookfair D L, Hadjimichael O, Moloney W C, Monson R R, Thompson W D, Wactawski-Wende J, Wagoner J K
Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Radiat Res. 1993 Jul;135(1):108-24.
The relationship between exposure to sparsely ionizing radiation and mortality due to cancers of hematopoietic and lymphopoietic tissues was studied among 12,955 women treated for benign gynecological disorders at any of 17 hospitals in New England or New York State and followed for an average of 25 years; 9770 women were treated by radiation (intracavitary 226Ra, external-beam X rays), while 3185 were treated by other methods, including curettage, surgery, and hormones. The average age at treatment was 46.5 years, and the mean dose to active bone marrow among irradiated women was 119 cGy. Forty deaths due to acute, myelocytic, or monocytic leukemia were observed among irradiated women. This number was 70% higher than expected based on U.S. mortality rates [standardized mortality ratio (SMR) = 1.7; 90% confidence interval (CI) 1.3-2.3]. A deficit was recorded among nonirradiated women, based on three observed deaths (SMR = 0.5; 90% CI 0.1-1.2). A well-defined gradient in the SMR with dose among exposed women was not detected. The SMR was highest within 5 years after irradiation but remained elevated even after 30 years. The temporal pattern differed by subtype of leukemia: excess mortality due to chronic myelocytic leukemia occurred almost exclusively within the first 15 years, whereas the SMR for acute leukemia, though also elevated, varied little over time. Cancers of lymphoreticular tissue occurred more often than expected based on U.S. mortality rates, but not appreciably differently for irradiated and nonirradiated women. There was little or no evidence of effects attributable to radiotherapy for chronic lymphocytic leukemia [relative risk (RR) = 1.1; 90% CI 0.5-3.0], Hodgkin's disease (RR = 0.9; 90% CI 0.3-3.2), non-Hodgkin's lymphoma (RR = 0.9; 90% CI 0.6-1.6), or multiple myeloma (RR = 0.6; 90% CI 0.3-1.4). These results corroborate previous findings indicating that acute and myelocytic leukemias are the most prominent malignancies after exposure to sparsely ionizing radiation, occurring in excess shortly after irradiation, and that lymphomas are either not caused by radiation or are induced only rarely.
在新英格兰或纽约州17家医院接受良性妇科疾病治疗的12955名女性中,研究了暴露于低剂量电离辐射与造血和淋巴组织癌症导致的死亡率之间的关系,并对她们进行了平均25年的随访;9770名女性接受了放射治疗(腔内226镭、外照射X射线),而3185名女性接受了其他治疗方法,包括刮宫、手术和激素治疗。治疗时的平均年龄为46.5岁,接受放射治疗的女性中活跃骨髓的平均剂量为119厘戈瑞。在接受放射治疗的女性中,观察到40例因急性、髓细胞性或单核细胞性白血病死亡。这一数字比根据美国死亡率预期的高出70%[标准化死亡比(SMR)=1.7;90%置信区间(CI)1.3 - 2.3]。在未接受放射治疗的女性中,基于3例观察到的死亡记录存在不足(SMR = 0.5;90% CI 0.1 - 1.2)。在暴露女性中未检测到SMR随剂量有明确的梯度变化。SMR在放射治疗后5年内最高,但即使在30年后仍保持升高。白血病亚型的时间模式有所不同:慢性髓细胞性白血病导致的超额死亡率几乎完全发生在前15年内,而急性白血病的SMR虽然也升高,但随时间变化不大。淋巴网状组织癌症的发生频率高于根据美国死亡率预期的,但在接受放射治疗和未接受放射治疗的女性中没有明显差异。几乎没有证据表明放射治疗对慢性淋巴细胞白血病[相对风险(RR)=1.1;90% CI 0.5 - 3.0]、霍奇金病(RR = 0.9;90% CI 0.3 - 3.2)、非霍奇金淋巴瘤(RR = 0.9;90% CI 0.6 - 1.6)或多发性骨髓瘤(RR = 0.6;90% CI 0.3 - 1.4)有影响。这些结果证实了先前的研究结果,表明急性和髓细胞性白血病是暴露于低剂量电离辐射后最突出的恶性肿瘤,在放射治疗后不久就会出现超额病例,并且淋巴瘤要么不是由辐射引起的,要么只是很少被诱导产生。